ICG-99mTc-nanocolloid vs. 99mTc-nanocolloid en een intraoperatieve injectie van ICG voor de schildwachtklierprocedure van prostaat kanker.

ICG-99mTc-nanocolloid vs. 99mTc-nanocolloid and and intraoperative ICG injection for sentinel node biopsy in patients with prostate cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28336

Enrollment

138

Registered

2014-08-12

Start date

2014-07-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer, sentinel lymph node

Interventions

On the morning of surgery patients will receive an transrectal-ultrasound guided intraprostatic or intratumoral injection with the hybrid tracer ICG-99mTc-nanocolloid (ARM 1) or 99mTc-nanocolloid (ARM

Eligibility

Inclusion criteria

Inclusion criteria: - patients >18 years of age - patients with histologically proven prostate cancer - patients with an increased risk of nodal metastasis according to the MSKCC nomogram (>10%) - scheduled for surgical (laparoscopic) prostatectomy including nodal dissection

Exclusion criteria

Exclusion criteria: - patients with a history of iodine allergy - patients with a hyperthyroid or thyroidal adenoma - patients with kidney insufficiency

Design outcomes

Primary

Measure	Time frame
Number of tumor positive lymph nodes.	—

Contacts

Public ContactH.G. Poel, van der

Department of Urology The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Plesmanlaan 121

h.vd.poel@nki.nl+31205129111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)